LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials

BACKGROUND: In a Phase 3 trial, the Janssen COVID-19 vaccine, Ad26.COV2.S, showed robust efficacy against severe–critical COVID-19 in countries where different SARS-CoV-2 variants were circulating. We evaluated Ad26.COV2.S-elicited antibody neutralizing activity against variants of concern (VOC) B.1...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Gars, Mathieu, Sadoff, Jerald, Jongeneelen, Mandy, Heerwegh, Dirk, Shukarev, Georgi, Truyers, Carla, de Groot, Anne Marit, Scheper, Gert, Hendriks, Jenny, Brandenburg, Boerries, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644272/
http://dx.doi.org/10.1093/ofid/ofab466.1638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644272/
http://dx.doi.org/10.1093/ofid/ofab466.1638

Ejemplares similares